Clinical efficacy of escitalopram combined with botulinum toxin A in patients with generalized anxiety disorder and comorbid headache

[1] Ababneh OH(2014)Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm Clinical & experimental ophthalmology 42 254-261

[2] Cetinkaya A(2012)The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity International journal of rehabilitation research Internationale Zeitschrift fur Rehabilitationsforschung Revue internationale de recherches de readaptation 35 36-39

[3] Kulwin DR(2015)Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults The Cochrane database of systematic reviews 4 Cd002919-1325

[4] Bakheit AM(2010)EFNS guideline on the treatment of tension-type headache - report of an EFNS task force European journal of neurology 17 1318-132

[5] Liptrot A(2014)Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study Pain research & management 19 126-266

[6] Newton R(2011)Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder Human psychopharmacology 26 258-1241

[7] Pickett AM(2019)Antidepressants for preventive treatment of migraine Current treatment options in neurology 21 18-229

[8] Banzi R(2021)Unilateral facial injection of botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice The Journal of Headache and Pain 22 38-758

[9] Cusi C(2021)Guideline for primary care of generalized anxiety disorder(2021) The Chinese Journal of General Practitioners 20 1232-637

[10] Randazzo C(2021)An update on botulinum toxin in neurology Neurologic clinics 39 209-607

[1] Ababneh OH(2014)Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm Clinical & experimental ophthalmology 42 254-261

[2] Cetinkaya A(2012)The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity International journal of rehabilitation research Internationale Zeitschrift fur Rehabilitationsforschung Revue internationale de recherches de readaptation 35 36-39

[3] Kulwin DR(2015)Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults The Cochrane database of systematic reviews 4 Cd002919-1325

[4] Bakheit AM(2010)EFNS guideline on the treatment of tension-type headache - report of an EFNS task force European journal of neurology 17 1318-132

[5] Liptrot A(2014)Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study Pain research & management 19 126-266

[6] Newton R(2011)Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder Human psychopharmacology 26 258-1241

[7] Pickett AM(2019)Antidepressants for preventive treatment of migraine Current treatment options in neurology 21 18-229

[8] Banzi R(2021)Unilateral facial injection of botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice The Journal of Headache and Pain 22 38-758

[9] Cusi C(2021)Guideline for primary care of generalized anxiety disorder(2021) The Chinese Journal of General Practitioners 20 1232-637

[10] Randazzo C(2021)An update on botulinum toxin in neurology Neurologic clinics 39 209-607